سعر ريافيرون ريتارد 160مكجم/1.2مل امبول 2026

Peginterferon alfa-2a solution for injection, 160 mcg/1.2 ml, single vial (Minapharm, Egypt).

• Chronic hepatitis C in adults with compensated liver disease, as part of combination regimens with other HCV antivirals (US label for PEGASYS).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Chronic hepatitis B (HBeAg-positive and HBeAg-negative) in adults with compensated liver disease and evidence of viral replication and liver inflammation (US label for PEGASYS).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions in adults (>40%): fatigue/asthenia, pyrexia, myalgia and headache.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity (urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens-Johnson syndrome) to alpha interferons or any component.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Autoimmune hepatitis; hepatic decompensation (Child-Pugh score >6, class B and C) in cirrhotic patients before treatment.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Contraindicated in neonates and infants because the US product contains benzyl alcohol; combination with ribavirin is contraindicated in pregnant women and men whose female partners are pregnant.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Boxed-level risks: alpha interferons may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic and infectious disorders; monitor closely and withdraw therapy with persistently severe or worsening signs.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Neuropsychiatric reactions including depression, suicidal and homicidal ideation and relapse of drug addiction; use with extreme caution in patients with a history of depression.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Bone marrow suppression, cardiovascular and cerebrovascular disorders, thyroid and other endocrine disorders, hyperglycemia, ophthalmologic, pulmonary disorders, colitis, pancreatitis, infections and hepatic decompensation in cirrhosis may occur; dose reduction or discontinuation may be required.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Theophylline (CYP1A2 substrates)Peginterferon alfa-2a inhibited CYP1A2 with a 25% increase in theophylline AUC; monitor theophylline levels and adjust dose.DailyMed (U.S. National Library of Medicine)
• MethadoneMethadone levels rose 10-15%; monitor for methadone toxicity.DailyMed (U.S. National Library of Medicine)
• Zidovudine / nucleoside analoguesMonitor for worsening neutropenia and/or anemia and other toxicities with nucleoside analogues.DailyMed (U.S. National Library of Medicine)

• When combined with ribavirin, birth defects and fetal death may occur: negative pregnancy test before therapy, two forms of effective contraception and monthly pregnancy tests are required.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk; weigh benefits of breastfeeding against maternal need. HIV-coinfected mothers should not breastfeed.General active-ingredient information · DailyMed (U.S. National Library of Medicine)